Answers are grounded in this paper and cite their sources.
Background Tuberculosis has become the world’s most lethal infectious disease. A major challenge in treating tuberculosis is the multidrug resistance of Mycobacterium tuberculosis to existing antibiotics. Therefore, there is an urgent need to discover new antituberculosis agents with unexploited mechanisms of action. The aim of the work was to develop inhibitors of mycobacterial leucyl-tRNA synthetase (LeuRS) with antibacterial activity.Materials and methods The virtual screening of compound collection containing about 250,000 ligands into aminoacyl-adenylate binding site of M. tuberculosis LeuRS was performed with AutoDock 4.2 software. The inhibitory activity of compounds toward recombinant LeuRS was studied in aminoacylation assay using 14C-labeled L-leucine. Antibacterial activity was investigated toward M. tuberculosis H37Rv strain under four different conditions.Results According to the data of biochemical screening, we have found M. tuberculosis LeuRS inhibitors among N-(5-Benzyl-thiazol-2-yl)-2-(1-phenyl-1H-tetrazol-5-ylsulfanyl)-acetamide deivatives, which decrease enzyme activity with IC50 values in micromolar range. The most promising compound, N-(5-Benzyl-thiazol-2-yl)-2-[4-(4-methoxy-phenyl)-1H-tetrazol-5-ylsulfanyl]-acetamide, reveals potent antibacterial activity with the best minimum inhibitory concentration (MIC) value of 4.7 µM.Conclusion N-(5-Benzyl-thiazol-2-yl)-2-(1-phenyl-1H-tetrazol-5-ylsulfanyl)-acetamide scaffold can be valuable for further biological research and chemical optimization.
No takes yet. Share an insight, caveat, or question.
Volynets et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: